MedTrace Logo

Clopidogrel Versus Ticagrelor in Type-2 Diabetes

NCT02742987 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2017-08-17

Study results available
· View outcomes & findings →

Summary

CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2 diabetes mellitus (T2DM) treated with percutaneous coronary intervention (PCI).

Conditions

Interventions

DRUG

Ticagrelor

Ticagrelor 90 mg twice daily

DRUG

Clopidogrel

Clopidogrel 150 mg once daily

DRUG

Standard medical therapy

Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions

Sponsors & Collaborators

  • Campus Bio-Medico University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-06-30
Completion
2015-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742987 on ClinicalTrials.gov